BofA raises target for HUTCHMED stock from USD 16.00 to USD 18.00

Published on 10/20/2026 at 21:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

HUTCHMED presents two Phase III studies at ESMO on October 25, 2026. HUTCHMED stock costs EUR 13.15 at Lang & Schwarz on October 20, 2026.

Analyst target and reporting date

BofA raised its HUTCHMED target from USD 16.00 to USD 18.00 on September 21, 2026.
HUTCHMED will present SAFFRON data on October 25, 2026 and SANOVO data on October 26, 2026.
HUTCHMED stock costs EUR 13.15 at Lang & Schwarz on October 20, 2026 at 9:35 p.m. CEST.
Second-quarter 2026 revenue was USD 139.14 million versus USD 304.16 million expected.

HCM, US44842L1035, Illustration mit AI erstellt.

HUTCHMED (China) Limited (ISIN US44842L1035) was trading at EUR 13.15 at Lang & Schwarz on October 20, 2026 at 9:35 p.m. CEST. BofA raised its price target for the company from USD 16.00 to USD 18.00 on September 21, 2026, according to TipRanks.

Two studies reach ESMO

The next major corporate date is October 25, 2026, when HUTCHMED is scheduled to present SAFFRON Phase III results in a Presidential Symposium at the European Society for Medical Oncology congress in Madrid. SANOVO results follow on October 26, 2026, in a Proffered Paper session, as StockTitan reported from the company release dated September 23, 2026.

The two studies test savolitinib with osimertinib in different lung cancer settings. SAFFRON reported statistically significant improvements in progression-free and overall survival on August 17, 2026, while SANOVO reported a significant progression-free survival benefit and a clinically meaningful overall survival benefit on August 31, 2026.

What does the target imply?

Using the USD 14.76 Nasdaq quote at 3:40 p.m. ET on October 20, 2026, the USD 18.00 BofA target lies 21.95 percent above the share price. The estimate is a useful counterweight to the latest operating comparison, but it is not a guarantee of future performance.

Revenue missed expectations

HUTCHMED reported USD 139.14 million of revenue for the second quarter of 2026 against a USD 304.16 million consensus estimate, while earnings per share came in at USD 0.05 versus USD 0.14 expected, according to MarketBeat on October 13, 2026. The revenue gap makes the upcoming clinical presentations especially important for the valuation narrative.

Trading stays the frame

HUTCHMED has a market capitalization of USD 2.6 billion as of October 20, 2026. Its Nasdaq 52-week range was USD 9.77 to USD 16.33 on the same date, leaving the current USD quote below the annual high while the company prepares its next data disclosures. The company is a healthcare drug manufacturer focused on targeted and immune-based treatments for cancer and immune-related diseases.

HUTCHMED was trading at EUR 13.15 at Lang & Schwarz on October 20, 2026 at 9:35 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of HUTCHMED stock.